Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

I agree that nothing is simple in biotech. Delays are to be expected. A perfect example is getting Oral Mucositis- Institutional Review Board (IRB) Approval instead of the expected first patient dosing. Apparently, the IRB met later than expected. Things like that are out of Leo's hands. But, it isn't surprising considering the holidays.

Of the three drugs you mention, I expect Brilacidin to bring in revenues first. Early 2016 is my guess.

It will be nice to see the following start:
http://cellceutix.com/cellceutix-reports-positive-results-of-brilacidin-in-microbiological-intent-to-treat-population-in-phase-2b-absssi-trial-additional-pharmacokinetic-information-to-be-submitted/#sthash.nu2TtEYD.dpbs

Study sites identified in the U.S. include MD Anderson Cancer Center at the University of Texas. A description of the study has now been submitted to www.clinicaltrials.gov and is expected to be published in the near term.

Watch for the posting to come up here:
https://clinicaltrials.gov/ct2/results?term=cellceutix




In Reply to 'Rdunn88'
Karin, the go ahead for P was a study, the question with the latest PPs run-up, is how much longer? will it take for either P,B or K to deliver sales??? It's nice to cheer and say how great everything is, but it's not that simple in the biotech world. Delays and disappointments are expected, so maybe the PPS got a little ahead of itself? If we all knew P,K and B will/would pass all their trials the PPs would be at 200...